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Background: Cardiovascular factors and low education are important risk factors of dementia. We provide
contemporary estimates of the proportion of dementia cases that could be prevented if modifiable risk factors were
eliminated, i.e., population attributable risk (PAR). Furthermore, we studied whether the PAR has changed across the
last two decades.
Methods: We included 7,003 participants of the original cohort (starting in 1990) and 2,953 participants of the
extended cohort (starting in 2000) of the Rotterdam Study. Both cohorts were followed for dementia until ten years
after baseline. We calculated the PAR of overweight, hypertension, diabetes mellitus, cholesterol, smoking, and
education. Additionally, we assessed the PAR of stroke, coronary heart disease, heart failure, and atrial fibrillation. We
calculated the PAR for each risk factor separately and the combined PAR taking into account the interaction of
risk factors.
Results: During 57,996 person-years, 624 participants of the original cohort developed dementia, and during 26,177
person-years, 145 participants of the extended cohort developed dementia. The combined PAR in the original cohort
was 0.23 (95 % CI, 0.05–0.62). The PAR in the extended cohort was slightly higher at 0.30 (95 % CI, 0.06–0.76). The
combined PAR including cardiovascular diseases was 0.25 (95 % CI, 0.07–0.62) in the original cohort and 0.33
(95 % CI, 0.07–0.77) in the extended cohort.
Conclusions: A substantial part of dementia cases could be prevented if modifiable risk factors would be
eliminated. Although prevention and treatment options of cardiovascular risk factors and diseases have improved,
the preventive potential for dementia has not declined over the last two decades.
Keywords: Dementia, Epidemiology, Population attributable risk, Risk factorsBackground
In recent years, it has become clear that cardiovascular
factors and low education are risk factors of dementia
[1–3]. As advocated by the recent World Alzheimer re-
port [3], most of these factors are potentially modifiable,
which provides an opportunity for prevention of dementia.
The magnitude of this potential for prevention can be esti-
mated via the population attributable risk (PAR) [4].* Correspondence: m.a.ikram@erasmusmc.nl
1Department of Epidemiology, Erasmus University Medical Center,
Wytemaweg 80, 3015 CN Rotterdam, The Netherlands
2Department of Neurology, Erasmus University Medical Center,
’s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
Full list of author information is available at the end of the article
© 2015 de Bruijn et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Few studies have estimated PAR for modifiable risk
factors of dementia [5–10]. However, results have been
inconsistent due to methodological variation. For in-
stance, some studies estimated PAR using data from
multiple different sources, which precludes proper ad-
justment for risk factors and only yields indirect approx-
imations of PAR [6, 8, 10]. Nevertheless, the combined
PAR of potentially modifiable risk factors of dementia
has been estimated to range from 8.4–50.7 % [6–9].
At the same time, converging evidence, including from
our own study, suggests that the incidence of dementia
has declined over the last decades [11–15]. Presumably,
this decline has been triggered by a better control ofal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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this is indeed the case, it is conceivable that previously
published PARs of modifiable risk factors for dementia
have now become an overestimation. There is thus an
urgent need for contemporary data on PAR of modifi-
able risk factors of dementia, because such updated
knowledge can better inform public health priorities on
preventive strategies against dementia. In this study, we
provide direct and contemporary estimates of PAR of
modifiable risk factors of dementia. Additionally, we
investigate how this PAR has changed across the last
two decades.
Methods
Setting and study population
This study was embedded within the Rotterdam Study, a
prospective population-based cohort study. In 1990, all
residents aged 55 and older residing in Ommoord, a
district of Rotterdam, the Netherlands, were invited. Of
the 10,215 invited inhabitants, 7,983 agreed to partici-
pate in the baseline examinations. In 2000, the cohort
was extended: again all residents aged 55 and older of
the same district were invited, except for the participants
that were already participating in the original cohort. Of
the 4,472 invitees, 3,011 agreed to participate. Follow-up
examinations take place every 3 to 4 years [16].
From the original cohort, we excluded 455 participants
because they were not properly screened for dementia,
482 participants because they had prevalent dementia,
and 43 participants for lack of follow-up information on
the dementia diagnosis. Finally, 7,003 participants were
included in the analyses. In the extended cohort, we
excluded 29 participants because they had prevalent
dementia and 29 for lack of follow-up information on
the dementia diagnosis. Finally, 2,953 participants were
included in the analysis. Even though a part of the ori-
ginal cohort still participated in 2000, those participants
were only included in the original, and not in the ex-
tended cohort. We aimed to avoid overlapping individ-
uals, since such a correlation would limit the assessment
of cohort effects.
The Rotterdam Study has been approved by the med-
ical ethics committee according to the Population Study
Act Rotterdam Study and written informed consent
was obtained.
Selection and measurement of risk factors
Potentially causal and modifiable risk factors for demen-
tia were chosen on the basis of previous literature [1–3].
The following risk factors were selected: overweight and
obesity, hypertension, diabetes mellitus, unfavorable chol-
esterol levels, smoking, and low educational level.
All risk factors were measured at baseline. Weight and
height were measured at the research center visit andbody mass index (BMI) was calculated as weight in kilo-
grams divided by length in meters squared. BMI was
categorized into four categories: underweight (<18.5),
normal weight (18.5–25), overweight (25–30), and obes-
ity (>30). Blood pressure was measured in sitting position
on the right arm and calculated as the average of
two measurements using a random-zero sphygmo-
manometer. Hypertension was defined as a blood
pressure ≥140/90 mmHg or use of blood pressure lower-
ing medication, prescribed for the indication of hyperten-
sion. Diabetes mellitus was defined as a fasting serum
glucose level ≥7.0 mmol/L, non-fasting serum glucose
level ≥11.1 mmol/L, or use of anti-diabetic medication.
Serum glucose, total cholesterol, and high-density lipo-
protein (HDL)-cholesterol levels were acquired by an
automated enzymatic procedure (Boehringer Mannheim
System). Medication use, educational level, and smoking
habits were assessed by interview. For people not tak-
ing lipid-lowering medication, total cholesterol/HDL-
cholesterol ratio was divided in quartiles using the
lowest category as the reference category. People using
lipid-lowering medication were added as the fifth cat-
egory and also compared to the reference category.
Educational level was categorized as low (primary edu-
cation or lower vocational education), intermediate
(secondary education or intermediate vocational edu-
cation), and high educational level (higher vocational
education or university). Smoking habits were catego-
rized as current, former, and never smoking.
Although stroke, coronary heart disease, heart failure,
and atrial fibrillation are cardiovascular diseases that
may result from cardiovascular risk factors and can be
modified only via secondary prevention, several studies
have shown that these diseases are related to dementia
or cognitive impairment, independently of cardiovascu-
lar risk factors [17–20]. We therefore assessed the PAR
of these factors in an additional analysis. A history of
stroke, coronary heart disease (myocardial infarction or
revascularization procedure), heart failure, and atrial fib-
rillation was evaluated using home interviews and con-
firmed by reviewing medical records [21, 22].
Assessment of dementia
Participants were screened for dementia at baseline and
at follow-up examinations using a three-step protocol
[11]. Screening was done using the Mini-Mental State
Examination (MMSE) and the Geriatric Mental Schedule
(GMS) organic level. Screen-positives (MMSE <26 or
GMS organic level >0) subsequently underwent an
examination and informant interview with the Cambridge
Examination for Mental Disorders in the Elderly [11].
Participants who were suspected of having dementia
underwent extra neuropsychological testing if necessary.
Additionally, for persons not visiting the research center,
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through computerized linkage of the study database and
digitized medical records from general practitioners and
the Regional Institute for Outpatient Mental Health Care.
When information on neuroimaging was required and
available, it was used for decision making on the diagnosis.
Ultimately, a consensus panel, led by a neurologist, de-
cided on the final diagnosis in accordance with stand-
ard criteria for dementia (DSM-III-R) [11]. Both the
original and the extended cohort were followed for de-
mentia until 10 years after baseline examinations: until
2000–2003 for the original cohort and until 2010–2012
for the extended cohort. Follow-up for dementia was
complete for 99.5 % of potential person-years in the
original cohort and for 98.5 % of potential person-years
in the extended cohort.
Statistical analyses
We imputed missing data on the investigated risk factors
(3.3 % in the original cohort and 6.7 % in the extended
cohort) using the mean of five imputations. Missing data
were imputed on age, sex, and all other investigated risk
factors. Differences between the original and the ex-
tended cohort were calculated using logistic regression
models, adjusting for age and sex where appropriate.
Analyses were performed using statistical software pack-
age SPSS 20.0.
We calculated PARs and corresponding 95 % confi-
dence intervals (CIs) using the Interactive Risk Attribut-
able Program (US National Cancer Institute) [23]. This
metric is also referred to as population attributable frac-
tion, or PAR%. We provide logit transformed 95 % CIs
accompanying the PARs as these are better interpret-
able and more stringent with regard to our combined
PAR estimates [24]. The PAR was estimated and
adjusted for confounding factors according to the
following formulae:
PAR ¼ 1−
X I
i¼1
XJ
j¼1ρijR
−1
ijj ð1Þ
where
Rijj ¼ Pr D ¼ 1jX ¼ xi;C ¼ cjð Þ
Pr D ¼ 1jX ¼ x1;C ¼ cjð Þ ð2Þ
and
ρij ¼ Pr X ¼ xi;C ¼ cj D ¼ 1j Þ
 ð3Þ
with D = 1 denoting presence of disease, X denoting ex-
posure with i levels, and C denoting a confounder with j
levels. Participants were censored at date of dementia,
date of death, or last date of follow-up, whichever came
first. The relative risk was estimated from a multivariable
Poisson model [23]. First, we calculated the PAR foroverweight and obesity, hypertension, diabetes mellitus,
unfavorable cholesterol levels, smoking, and low educa-
tional level. Second, we calculated the PAR of stroke,
coronary heart disease, heart failure, and atrial fibrilla-
tion. We calculated the PAR for each risk factor separ-
ately as well as the combined PAR per cohort. Many risk
factors have a coinciding effect on the etiology of de-
mentia. Therefore, the combined PAR cannot be esti-
mated by the sum of the separate PARs as this would
lead to an overestimation. The advantage of the statis-
tical program used in this study is that it takes into
account that a disease case can simultaneously be attrib-
uted to more than one risk factor. Hence, it takes into
account the overlap between the PARs of each risk fac-
tor when estimating the combined PAR. The combined
PAR included the PARs of modifiable risk factors which
were associated to dementia in the expected direction in
our study, meaning the relative risk was above one.
PARs cannot be calculated using a relative risk below
one as this will result in a PAR which cannot be inter-
preted [25].
Every PAR was adjusted for age, sex, and all other risk
factors included in the model. Age was added per 5-year
categories into the models. Because of a small number
of people in the oldest age categories, the oldest age
category of both cohorts comprised people 85 years of
age and older.
Results
Baseline characteristics
Baseline characteristics of the two study populations are
provided in Table 1. During a mean follow-up of
8.3 years (standard deviation (SD) 2.9), 624 participants
of the original cohort developed dementia and 1,756
participants died. During a mean follow-up of 8.9 years
(SD 2.3), 145 participants of the extended cohort devel-
oped dementia and 429 participants died. Cut-offs for
quartiles of total cholesterol/HDL cholesterol ratio were:
4.1, 5.0, and 6.1 in the original cohort and 3.6, 4.3, and
5.2 in the extended cohort. Participants in the extended
cohort were younger and had higher educational levels
than those in the original cohort. Overweight and
obesity, hypertension, diabetes mellitus, use of lipid-
lowering medication, former smoking, and stroke were
more prevalent in the extended cohort. Additionally,
people had lower total cholesterol levels, higher HDL-
cholesterol levels, and less heart failure and coronary
heart disease in the extended cohort than in the original
cohort (Table 1).
Population attributable risk (PAR)
In the original cohort, smoking (PAR, 0.07; 95 % CI,
0.02–0.23) and lower educational level (PAR, 0.07; 95 %
CI, 0.00–0.90) had the largest PARs, followed by diabetes
Table 1 Baseline characteristics of the original and the
extended cohort of the Rotterdam Study
RS-I RS-II P value for
differenceN = 7,003 N = 2,953
Age, years 69.4 (9.1) 65.0 (8.3) <0.001
Sex, female 4187 (59.8 %) 1661 (56.2 %) 0.15
Body mass index
<18.5 69 (1.0 %) 15 (0.6 %) 0.65
18.5–25 2486 (37.5 %) 790 (29.9 %) Reference
25–30 3097 (46.7 %) 1286 (48.6 %) <0.001
>30 977 (14.7 %) 555 (21.0 %) <0.001
Hypertension 3793 (56.3 %) 1688 (61.9 %) <0.001
Diabetes mellitus 727 (10.5 %) 319 (10.9 %) 0.001
Total cholesterol, mmol/L 6.6 (1.2) 5.8 (1.0) <0.001
HDL cholesterol, mmol/L 1.3 (0.4) 1.4 (0.4) 0.004
Lipid lowering medication 164 (2.3 %) 367 (12.5 %) <0.001
Smoking
Former 2848 (41.7 %) 1381 (47.4 %) 0.001
Current 1560 (22.8 %) 678 (23.3 %) 0.60
Educational level
Intermediate 2540 (37.3 %) 1429 (49.4 %) <0.001
Low 3700 (54.3 %) 975 (33.7 %) <0.001
Stroke 175 (2.5 %) 94 (3.2 %) <0.001
Coronary heart disease 535 (8.4 %) 163 (6.1 %) 0.04
Heart failure 220 (3.3 %) 31 (1.2 %) 0.01
Atrial fibrillation 316 (4.9 %) 79 (3.6 %) 0.44
Data are presented as means (standard deviations) or numbers (percentages).
Percentages are calculated without missing data. Abbreviations: RS-I, Rotterdam
Study I, original cohort; RS-II, Rotterdam Study II, extended cohort; N , number of
participants; HDL, High density lipoprotein. Differences between the original and
extended cohort were calculated using logistic regression models, adjusting for
age and sex where appropriate
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(PAR, 0.04; 95 % CI, 0.00–0.44) and higher total choles-
terol/HDL cholesterol ratio (PAR, 0.03; 95 % CI, 0.00–
0.73). Overweight and obesity were not related to
dementia in the expected direction. The combined PAR
in the original cohort was 0.23 (95 % CI, 0.05–0.62;
Table 2).
In the extended cohort, hypertension (PAR, 0.16; 95 %
CI, 0.02–0.62), lower educational level (PAR, 0.12; 95 % CI,
0.00–0.89), and diabetes mellitus (PAR, 0.06; 95 % CI,
0.02–0.19) had the largest PARs. Overweight and obesity,
higher total cholesterol/HDL-cholesterol ratio, and smok-
ing were not related to dementia in the expected direction.
The combined PAR in the extended cohort was 0.30
(95 % CI, 0.06–0.76; Table 2).
When cardiovascular diseases were included into the
model, the combined PAR was 0.25 (95 % CI, 0.07–0.62)
in the original cohort and 0.33 (95 % CI, 0.07–0.77) inthe extended cohort. Atrial fibrillation and stroke had
the largest PARs in the original cohort, whereas coron-
ary heart disease and stroke had the largest PARs in the
extended cohort (Table 3).
Discussion
Within the population-based Rotterdam Study, we found
that about one quarter to one third of dementia cases
could potentially be prevented through optimal preven-
tion or treatment of cardiovascular risk factors and
diseases and improvement of educational level. This pro-
portion has not declined between the original cohort of
1990–2000 and the extended cohort of 2000–2010, al-
though we did observe a shift in the relative importance
of individual factors.
Before these results can be interpreted, some meth-
odological issues need to be mentioned. The strengths of
the present study are the prospective, population-based
design and almost complete dementia case finding. Add-
itionally, information on a relatively wide range of risk
factors was assessed, allowing the calculation of PARs on
various potentially modifiable risk factors. Furthermore,
a statistical approach, which takes into account the
interaction between risk factors when estimating the
combined PAR, was used.
We recognize that our study also has limitations. PAR
calculations should always be interpreted with caution as
they rely on assumptions which may be improbable in
practice [26, 27]. For instance, the model assumes that a
risk factor can be successfully treated in every person
and that removing one risk factor would not induce
changes in the other factors, which is unlikely. Further-
more, PAR calculations assume that, when a risk factor
is successfully treated, the harming effect of the risk fac-
tor completely disappears, which too is unlikely as risk
factors might have already caused irreversible damage
before treatment is started. Moreover, if we prevent a
dementia case caused by these cardiovascular risk fac-
tors, this person might still suffer from dementia caused
by other factors. Therefore, the proportion that can ac-
tually be prevented in practice might be lower than sug-
gested by the PAR [26, 27]. We selected potentially
causal and modifiable risk factors of dementia based on
previous literature [1–3]. However, it should be noticed
that, within this study, this causal relationship could not
be established. In particular, findings related to cardio-
vascular diseases should be interpreted with caution as
these may have an association with dementia through
shared risk factors. Paradoxically, treatment might even
increase the occurrence of dementia, if the people that
are treated live longer.
In our study, we did not find many statistically signifi-
cant associations between these risk factors and the risk
of dementia. This might have various explanations. First,
Table 2 Population attributable risk (PAR) of risk factors in the original and extended cohort
RS-I RS-II
n/N 624/7,003 n/N 145/2,953
HR (95 % CI) PAR (95 % CI)
per category
Combined PAR per
risk factor (95 % CI)
HR (95 % CI) PAR (95 % CI)
per category
Combined PAR per
risk factor (95 % CI)
Body mass index NA NA
<18.5 1.25 (0.62–2.56) 0.00 (0.00–0.08) 1.41 (0.19–10.49) 0.00 (0.00–0.67)
25–30 0.96 (0.81–1.15) NA 0.90 (0.61–1.32) NA
>30 0.84 (0.65–1.08) NA 0.81 (0.48–1.36) NA
Hypertension 1.07 (0.89–1.27) 0.04 (0.00–0.44) 1.25 (0.81–1.94) 0.16 (0.02–0.62)
Diabetes mellitus 1.31 (1.05–1.63) 0.04 (0.01–0.09) 1.51 (0.96–2.37) 0.06 (0.02–0.19)
Cholesterol/HDL cholesterol 0.03 (0.00–0.73) NA
Quartile 2 1.04 (0.83–1.30) 0.01 (0.00–0.82) 0.64 (0.39–1.04) NA
Quartile 3 1.08 (0.86–1.35) 0.02 (0.00–0.30) 0.86 (0.53–1.39) NA
Quartile 4 1.04 (0.83–1.32) 0.01 (0.00–0.70) 0.72 (0.42–1.21) NA
Lipid lowering medication 0.64 (0.28–1.45) NA 1.03 (0.60–1.74) 0.00 (0.00–1.00)
Smoking 0.07 (0.02–0.23) NA
Former 1.10 (0.90–1.34) 0.03 (0.00–0.23) 1.00 (0.68–1.48) 0.01 (0.00–1.00)
Current 1.33 (1.04–1.71) 0.04 (0.02–0.10) 0.86 (0.48–1.52) NA
Educational level 0.07 (0.00–0.90) 0.12 (0.00–0.89)
Intermediate 0.99 (0.68–1.45) NA 1.01 (0.57–1.78) 0.00 (0.00–1.00)
Low 1.13 (0.78–1.63) 0.08 (0.00–0.66) 1.32 (0.73–2.36) 0.11 (0.02–0.51)
Total 0.23 (0.05–0.62) 0.30 (0.06–0.76)
Estimates represent hazard ratios (95 % CIs) and population attributable risks (PARs; 95 % CIs). Models were adjusted for age, sex, and for body mass index, hypertension,
diabetes mellitus, total cholesterol/HDL cholesterol ratio, lipid-lowering medication, smoking, and educational level, if appropriate. For some risk factors, PARs could not
be calculated as these risk factors were not related to dementia in the expected direction; these PARs are therefore not applicable (indicated with NA) [25]
Abbreviations: RS-I Rotterdam Study I, original cohort, RS-II Rotterdam Study II, extended cohort, HR Hazard ratio, CI Confidence interval, n Number of cases, N Number of
people at risk, PAR Population attributable risk, NA Not applicable, HDL High density lipoprotein
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single risk factor can therefore be relatively small and
non-significant. However, the preventive potential of all
risk factors combined can still be substantial. Second,
the sample size was limited, which might have preventedTable 3 Population attributable risk (PAR) of cardiovascular diseases
RS-I
n/N 624/7,003
HR (95 % CI) Combined PAR per risk factor
Total without CVD 0.23 (0.05–0.62)
Stroke 1.43 (1.00–2.04) 0.02 (0.00–0.05)
Coronary heart disease 1.00 (0.73–1.38) 0.00 (0.00–1.00)
Heart failure 0.87 (0.59–1.28) NA
Atrial fibrillation 1.32 (0.99–1.77) 0.02 (0.01–0.06)
Total including CVD 0.25 (0.07–0.62)
Estimates represent hazard ratios (95 % CIs) and population attributable risks (PARs; 95
hypertension, diabetes mellitus, total cholesterol/HDL cholesterol ratio, lipid-lowering m
and atrial fibrillation, if appropriate. For some risk factors, PARs could not be calculated
PARs are therefore not applicable (indicated with NA) [25]
Abbreviations: RS-I Rotterdam Study I, original cohort, RS-II Rotterdam Study II, extended
CI Confidence interval, PAR Population attributable risk; CVD, Cardiovascular disease; NAthe finding of statistically significant results because of
low power and because smaller subgroups for the risk
factors, such as untreated and treated hypertension,
could not be formed. Third, baseline risk factors were
used, whereas the risk factor profile might have changedin the original and extended cohort
RS-II
n/N 145/2,953
(95 % CI) HR (95 % CI) Combined PAR per risk factor (95 % CI)
0.30 (0.06–0.76)
1.70 (0.86–3.37) 0.03 (0.01–0.13)
1.38 (0.79–2.43) 0.03 (0.00–0.20)
0.33 (0.04–2.39) NA
0.36 (0.13–0.97) NA
0.33 (0.07–0.77)
% CIs). Models were adjusted for age and sex, and for body mass index,
edication, smoking, educational level, stroke, coronary heart disease, heart failure,
as these risk factors were not related to dementia in the expected direction; these
cohort, n Number of cases, N Number of people at risk, HR Hazard ratio,
, Not applicable
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tions. Fourth, the effect of cardiovascular risk factors
might be small because of the competing risk of cardio-
vascular mortality. People might die due to those risk
factors before dementia occurs. Fifth, it has been sug-
gested that the effect of several cardiovascular risk fac-
tors on the risk of dementia changes with increasing age.
Studies have shown that obesity, hypertension, and high
cholesterol levels were only related to an increased risk
of dementia when assessed at midlife [28–30]. Since the
participants in our study populations were older, we
were not able to assess such midlife effects, possibly
leading to an underestimation of our results. Although
our data collection was extensive, we did not have infor-
mation on some important modifiable risk factors, such
as physical activity, dietary habits, depression, and social
engagement, which might have led to an underestima-
tion of our results. We imputed missing data on investi-
gated risk factors, which may have introduced some
misclassification. However, we hypothesized that exclud-
ing participants with missing data from our analyses
would have resulted in more bias, given that missing
data usually does not occur at random. A final limi-
tation is that most participants of the Rotterdam
Study are Caucasians and live in a middle-income
district of Rotterdam, which limits the generalizability of
our results.
We found that the PAR of modifiable risk factors of
dementia was about one quarter to one third and has
not declined across the last two decades. These findings
have several implications. First, from a public health
point of view, this suggests that despite the seemingly
declining incidence of dementia, the potential for further
reduction of dementia is still substantial. Second, it re-
mains pivotal to find novel risk factors that can explain
the remaining two thirds of dementia cases. Third, even
though the combined PAR did not decline, we did find
that the contribution of individual risk factors had chan-
ged across the two decades. For example, the PARs of
hypertension and to a lesser extent of diabetes were
higher in the extended cohort. Although treatment and
preventive options for cardiovascular risk factors have
improved over the past decades, the prevalence of vari-
ous cardiovascular risk factors, such as hypertension,
diabetes, and obesity has increased [31–33]. Correspond-
ingly, we found that participants in the extended cohort
had a higher prevalence of these risk factors, partly
explaining the higher PARs. Conversely, we found a de-
cline in the PARs of other cardiovascular risk factors,
such as smoking and unfavorable cholesterol levels.
Smoking had a large effect on the burden of dementia
in the original cohort, which decreased dramatically
in the extended cohort. Successful anti-smoking cam-
paigns are an obvious explanation for these findings. Acounterargument, however, is that the prevalence of
current smokers was comparable between the two co-
horts. The reduction of the effect of unfavorable choles-
terol levels might be explained by the large increase in
use of lipid-lowering medication in the extended cohort.
Another interesting observation was the effect of educa-
tional level, which was higher in the extended cohort
than in the original cohort. Conventionally, educational
attainment is considered a reflection of cognitive reserve
built up earlier in life. However, this has not always been
the case in older Dutch generations, where many people
were unable to achieve their educational potential due to
the Second World War. This might have led to a dis-
crepancy between educational attainment and corre-
sponding cognitive reserve. In the original cohort of
the Rotterdam Study, this phenomenon might have been
more pronounced, explaining the higher prevalence but
lower PAR of low educational level compared to the ex-
tended cohort.
As for cardiovascular diseases, atrial fibrillation had an
effect on the burden of dementia in the original cohort,
but not in the extended cohort. These results might be
explained by improved prevention of ischemic stroke in
patients with atrial fibrillation [34]. In contrast, we found
a stronger effect of stroke and coronary heart disease in
the extended cohort than in the original cohort. This
might seem counter-intuitive, since preventive and treat-
ment options for these diseases have improved in the
same time-period. However, these findings could be
explained by the fact that because of improved treat-
ments, people with cardiovascular disease live longer
and therefore are at an increased risk of developing
dementia [35].
The combined PAR we found is very much in line with
a recent report that was based on meta-analyses of stud-
ies, which mostly used data from the nineties [8]. We
calculated PARs directly using original data from 1990–
2000 and 2000–2010 and, more importantly, took into
account interaction between risk factors. Our study
therefore adds important veracity to the estimates of
PAR. However, given that PAR calculations rely on the-
oretical assumptions, future research is necessary to ob-
serve the actual effect of risk factor improvement on the
risk of dementia. Furthermore, other studies should also
focus on identifying novel modifiable risk factors for
dementia.
Conclusions
We found that the potential of prevention of dementia
through proper control of modifiable risk factors is
about one quarter to one third and has not declined over
the last two decades. As this is currently one of the main
options to diminish the burden of dementia, public
health interventions are urgently needed.
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